SHL to Invest 40 Million USD in 2013 to Significantly Expand Production Facilities

   SHL to Invest 40 Million USD in 2013 to Significantly Expand Production

  PR Newswire

  TAOYUAN, Taiwan, Feb. 22, 2013

TAOYUAN, Taiwan, Feb. 22, 2013 /PRNewswire/ -- SHL announced plans this week
to expand production facilities in Taiwan. A leader in the field of drug
delivery devices such as auto injectors and pen injectors, SHL has continued
to invest heavily in facilities, advanced machinery and R&D. With the rapid
growth of the biologic injectable market, device suppliers are under pressure
to broaden the range of services that they can provide. SHL has responded by
making significant capital investments such as the 40 Million USD that will be
spent this year alone.

(Photo: )

CEO Roger Samuelsson commented, "Five years ago I signed a letter of intent
with the Taiwan government promising to invest 100 Million USD here. We kept
our promise and even completed that investment early. Now we will spend
another 40 Million USD for 2013. Our auto injector business is one of the key
drivers to this expansion of production capacity. Our customers are bringing
more biologics to market and SHL is going to ensure that we meet their needs."

This year SHL will invest primarily in molding, material handling, assembly
and automation capabilities. Production will be ramped up at several
facilities in Taiwan, Taoyuan One and various NanKan sites. Increased capacity
will allow SHL the flexibility to provide higher quantities of devices each
month. In addition to auto injectors, SHL produces pen injectors, infusors and
inhaler systems. The company now has well over 2,200 staff globally and will
be hiring several hundred new employees in Taiwan this year.

About SHL

SHL is the world's largest privately-owned designer, developer and
manufacturer of advanced drug delivery devices. We have over 2,200 staff
globally, with our primary design centers located in the USA and Sweden and
manufacturing centers located in Asia.

SHL supplies auto injectors, pen injectors and inhaler systems to global
pharmaceutical and biotech companies. Significant investment in R&D has
enhanced our broad pipeline of "next generation" drug delivery systems. These
innovative devices include a range of disposable and reusable injectors with
fixed or variable dosing, enhanced precision and the ability to accommodate
high viscosities.

Our organization consists of several distinct group companies:

  *SHL Medical Designs, develops and manufactures advanced drug delivery
    devices for leading pharmaceutical and biotech companies
  *SHL Healthcare Develops and manufactures equipment solutions for home,
    hospital and long term care use SHL Technologies
  *Provides contract manufacturing and engineering services for the
    production of complex medtech and industrial products
  *SHL Pharma Provides final assembly, labeling and packaging services of
    drug delivery devices to the pharmaceutical and biotechnology industries

For additional information visit or contact us at SHL Media Contact Steven R. KaufmanMarketing Director

Press spacebar to pause and continue. Press esc to stop.